ABSTRACT
Objective: The aim of this study was to evaluate fertility-sparing therapy in young patients with endometrial carcinoma
Methodology: This prospective study was carried out on 8 patients with clinical and radio-graphic stage IA, well differentiated endometrioid adenocarcinoma of the endometrium in Alzahra hospital, Tabriz, Iran. Treatment comprised high-dose megestrol acetate. Dilatation and curettage was repeated every three months
Results: The mean age of the patients was 30 [SD,3.21] years [range 24-35]. Of the 8 patients, 7 [87.5%] achieved complete response. The mean time to response was 6.5 months [range 3-9]. Of the complete responders, 3 of 7[42.8%] had recurrence; one patient underwent immediate hysterectomy, and 2 were successfully treated with second-line therapy and both subsequently conceived. Conception occurred in 3 of 7 patients [42.8%], in two more than once, However successful pregnancy occurred only in two patients. One patient developed Concomitant ovarian adenocarcinoma
Conclusions: High dose progestin therapy can be an effective fertility-sparing treatment in young patients with well differentiated stage IA endometrial endometrioid cancer confined to endometrium. However, close follow up is required because of risks of conservative treatment